Download PDF
Aktuelle Neurologie 2003; 30(4): 184-187
DOI: 10.1055/s-2003-39114
Arzneimitteltherapie
© Georg Thieme Verlag Stuttgart · New York

Temozolomid in der Behandlung maligner Gliome

Treatment of Malignant Gliomas with TemozolomideT.  Hundsberger1 , D.  Koch2 , S.  Klimpe1 , U.  Schlegel3
  • 1Klinik und Poliklinik für Neurologie (Direktorin: Prof. Dr. med. Marianne Dieterich), Universitätsklinikum Mainz
  • 2Klinik und Poliklinik für Neurochirurgie, Universitätsklinik Mainz (Direktor: Prof. Dr. med. Dr. h. c. Axel Perneczky)
  • 3Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn (Direktor: Prof. Dr. med. Thomas Klockgether)
Further Information

Publication History

Publication Date:
08 May 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Temozolomid (Handelsname Temodal®) ist ein orales, alkylierendes Chemotherapeutikum, das zur Behandlung von malignen Gliomen beim Rezidiv oder Progress seit 1999 europaweit zugelassen ist. In dieser Übersicht sollen Pharmakologie, Nebenwirkungen und Indikationen für den Einsatz von Temozolomid bei malignen Gliomen dargestellt werden. Ferner wird auf aktuelle Therapiestudien eingegangen, deren Ergebnisse einen Einfluss auf die zukünftigen Einsatzmöglichkeiten von Temozolomid in der Neuroonkologie haben könnten.

Abstract

Temozolomide is an orally administered, alkylating agent with approval for recurrent and progressive malignant gliomas. Here we review the pharmacological properties of temozolomide, its possible side effects and current indications for the treatment of malignant gliomas. Some current treatment trials on temozolomide are discussed, which may have an impact on its role in future Neuro-Oncology.

Literatur

  • 1 DeAngelis L. Brain Tumors.  N Engl J Med. 2001;  344 114-123
    CrossrefPubMedGoogle Scholar
  • 2 Hill J R, Kuriyama N, Kuriyama H. et al . Molecular genetics of brain tumors.  Arch Neurol. 1999;  56 439-441
    CrossrefPubMedGoogle Scholar
  • 3 Hofer S, Herrmann R. Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage.  J Cancer Res Clin Oncol. 2001;  127 91-95
    CrossrefPubMedGoogle Scholar
  • 4 Cairncross G, Macdonald D, Ludwin S. et al . Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 1994;  12 2013-2021
    PubMedGoogle Scholar
  • 5 van den Bent M J, Kros J M, Heimans J J. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine.  , CCNU and vincristine chemotherapy et al. Dutch Neuro-oncology Group. Neurology. 1998;  51 1140-1145
    PubMedGoogle Scholar
  • 6 Streffer J, Schabet M, Bamberg M. et al . A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.  J Neurol. 2000;  247 297-302
    PubMedGoogle Scholar
  • 7 The Medical Research Council Brain Tumor Working Party . Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial.  J Clin Oncol. 2001;  19 509-518
    PubMedGoogle Scholar
  • 8 Chamberlain M C, Jaeckle K A. Medical Research Council adjuvant trial in high-grade gliomas.  J Clin Oncol. 2001;  19 3997-3999
    PubMedGoogle Scholar
  • 9 DeAngelis L M, Burger P C, Green S B. et al . Malignant glioma: who benefits from adjuvant chemotherapy?.  Ann Neurol. 1998;  44 691-695
    CrossrefPubMedGoogle Scholar
  • 10 Weller M. Interdisziplinäre Leitlinien für die Diagnostik und Therapie supratentorieller Gliome des Erwachsenenalters.  Fassung vom 19.01.2002 (www.neuroonkologie.de)
    Google Scholar
  • 11 Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.  Lancet. 2002;  359 1011-1018
    CrossrefPubMedGoogle Scholar
  • 12 Wong E T, Hess K R, Gleason M J. et al . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.  J Clin Oncol. 1999;  17 2572-2578
    PubMedGoogle Scholar
  • 13 Raymond E, Izbicka E, Soda H. et al . Activity of temozolomide against human tumor colony-forming units.  Clin Cancer Res. 1997;  3 1769-1774
    PubMedGoogle Scholar
  • 14 Patel M, McCully C, Godwin K. et al . Plasma and cerebrospinal fluid pharmacokinetics of temozolomide.  Proc Am Soc Clin Oncol. 1995;  14 461
    PubMedGoogle Scholar
  • 15 Brock S B, Newlands E S, Steven R. et al . Phase I trial of temozolomide using an extended continuous oral schedule.  Cancer Res. 1998;  58 4363-4367
    PubMedGoogle Scholar
  • 16 Yung W K, Prados M D, Yaya-Tur R. et al . Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.  J Clin Oncol. 1999;  17 2762-2771
    PubMedGoogle Scholar
  • 17 Yung W K, Albright R E, Olson J. et al . A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse.  Br J Cancer. 2000;  83 588-593
    CrossrefPubMedGoogle Scholar
  • 18 Brada M, Hoang-Xuan K, Rampling R. et al . Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.  Ann Oncol. 2001;  12 259-266
    CrossrefPubMedGoogle Scholar
  • 19 Osoba D, Brada M, Yung W K. et al . Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.  J Clin Oncol. 2000;  18 1481-1491
    PubMedGoogle Scholar
  • 20 Stupp R, Dietrich P Y, Ostermann K S. et al . Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.  J Clin Oncol. 2002;  20 1375-1382
    CrossrefPubMedGoogle Scholar
  • 21 Chinot O L, Honore S, Dufour H. et al . Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.  J Clin Oncol. 2001;  19 2449-2455
    PubMedGoogle Scholar
  • 22 van den Bent M J, Keime-Guibert F, Brandes A A. et al . Temozolomide chemotherapy in recurrent oligodendroglioma.  Neurology. 2001;  57 340-342
    PubMedGoogle Scholar
  • 23 Stupp R, Gander M, Leyvraz S. et al . Current and future developments in the use of temozolomide for the treatment of brain tumours.  Lancet Oncol. 2001;  2 552-560
    CrossrefPubMedGoogle Scholar
  • 24 Friedman H S, McLendon R E, Kerby T. et al . DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.  J Clin Oncol. 1998;  16 3851-3857
    PubMedGoogle Scholar
  • 25 Hirose Y, Berger M S, Pieper R O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.  Cancer Res. 2001;  61 1957-1963
    PubMedGoogle Scholar
  • 26 Brandes A A, Vastola F, Basso U. Temozolomide in glioblastoma multiforme of the elderly.  Tumori. 2002;  88 69-70
    PubMedGoogle Scholar
  • 27 Koch D, Hopf N J, Hopf H C. et al . Behandlung maligner Gliome mit Temozolomid - Klinische Erfahrungen an 48 Patienten.  Akt Neurol. 2001;  28 (Suppl 2) 597
    PubMedGoogle Scholar
  • 28 Newlands E S, O'Reilly S M, Glaser M G. et al . The Charing Cross Hospital experience with temozolomide in patients with gliomas.  Eur J Cancer. 1996;  32 2236-2241
    CrossrefPubMedGoogle Scholar

Dr. med. Thomas Hundsberger

Klinik und Poliklinik für Neurologie · Universitätsklinikum Mainz

Langenbeckstraße 1

55101 Mainz

Email: tom.hundsberger@uni-mainz.de